Are we under-monitoring in scleroderma ILD? Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq

Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld

• Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-ba…
• https://x.com/RichardPAConway/status/1858913124285653396/photo/1

Does CVD mortality risk change after stopping GC in RA? ➡️28078 incident GC users ➡️Incr mortality risk from CVD &infections persists post-cessation ➡️Risk never returns to pre-GC level after prolonged use ⏩Use GC at lowest dose for shortest time possible Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke

• https://x.com/DrMiniDey/status/1858914634256052586/photo/1
• https://x.com/DrMiniDey/status/1858914634256052586/photo/1

Ab2674 #ACR24 ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12 ➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M @RheumNow https://t.co/pFOo86tJTx

• https://x.com/DrMiniDey/status/1858919164171481201/photo/1

An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatment accordingly. #ACR24 @RheumNow ABST#2674 https://t.co/YTThYiiLpZ

• https://x.com/JihaRheum/status/1858920170443469029/photo/1

#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ

• #ACR 2024 BEST Abstracts from Day 1 | RheumNow

Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

• https://x.com/Janetbirdope/status/1858892960063963347/photo/1

In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

• https://x.com/RHEUMarampa/status/1858893649821516094/photo/1
• https://x.com/RHEUMarampa/status/1858893649821516094/photo/1

Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E

• https://x.com/i/web/status/1858895508363776345
• https://x.com/synovialjoints/status/1858895508363776345/photo/1